美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

SPDR S&P Biotech ETF

154.18

+0.15000.10%

盤前：155.321.14+0.74%04:08 EDT

成交量：885.33萬

成交額：13.69億

市值：106.00億

市盈率：8.46

高：156.04

開：154.37

低：152.50

收：154.03

52周最高：169.89

52周最低：93.49

股本：6,875.00萬

流通股本：6,875.00萬

量比：1.08

換手率：12.88%

股息：0.57

股息率：0.37%

每股收益(TTM):18.23

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

醫療保健板塊快訊：市場動態綜述

醫療保健板塊綜述：市場快訊

上海：完善上海市重點產業地圖，聚焦集成電路、生物醫藥、人工智能三大先導產業

民祥生物醫藥被出具警示函，涉未披露年報等

花旗(C.US)調整北美醫療健康投行團隊強化醫療賽道核心競爭力

辰欣藥業等成立生物科技公司

生物醫藥賽道迎來機構扎堆調研商業化與全球化進展成關注重點

人工智能公司Anthropic已告知部分投資者，該公司計劃進一步拓展醫療保健與生物學領域業務。

醫療板塊綜述：市場快評

醫療保健板塊動態：市場速評

新聞稿：Ernexa Therapeutics 引入資深生物技術高管 David Polinsky 加入董事會，為臨床階段衝刺蓄力

醫療保健板塊市場動態速覽

港股生物醫藥股盤初走高，藥明康德股價突破200港元關口創歷史新高

醫療保健板塊動態：市場快訊匯總

人民健康保險天津分公司被罰28萬，涉欺騙投保人

梁振英：在醫療健康領域香港也可成為「超級聯繫人」

醫療保健板塊市場快訊

醫療健康板塊綜述：市場動態快報

人保健康天津分公司因欺騙投保人被罰28萬元一人被終身禁業

胡偉獲批擔任人保健康董事

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/XBI/news?page=10"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"XBI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XBI\",,,,,undefined,":{"symbol":"XBI","market":"US","secType":"STK","nameCN":"SPDR S&P Biotech ETF","latestPrice":154.18,"timestamp":1789588800000,"preClose":154.03,"halted":0,"volume":8853285,"hourTrading":{"tag":"盘前","latestPrice":155.32,"preClose":154.18,"latestTime":"04:08 EDT","volume":162,"amount":25095.927059999998,"timestamp":1789632500554,"change":1.14,"changeRate":0.007394,"amplitude":0.004605},"delay":0,"changeRate":0.0009738362656625701,"floatShares":68750000,"shares":68750000,"eps":18.23,"marketStatus":"盤前交易","change":0.15,"latestTime":"09-17 04:19:18 EDT","open":154.37,"high":156.04,"low":152.5,"amount":1368574083.6516001,"amplitude":0.022983,"askPrice":155.7,"askSize":800,"bidPrice":155.19,"bidSize":1,"shortable":3,"etf":1,"ttmEps":18.23,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789651800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":154.18,"sharesOutstanding":63325000,"nav":154.028797,"aum":10385391642.43,"dividendRate":0.003696,"bidAskSpread":0.000229,"preHourTrading":{"tag":"盘前","latestPrice":155.32,"preClose":154.18,"latestTime":"04:08 EDT","volume":162,"amount":25095.927059999998,"timestamp":1789632500554,"change":1.14,"changeRate":0.007394,"amplitude":0.004605},"postHourTrading":{"tag":"盘后","latestPrice":154.5,"preClose":154.18,"latestTime":"19:53 EDT","volume":37711,"amount":5808520.5381,"timestamp":1789602836010,"change":0.32,"changeRate":0.002075,"amplitude":0.004216},"volumeRatio":1.077362913566643,"optionData":{"bulkOrders":[{"symbol":"XBI","call":true,"expireDate":1797570000000,"strike":"170.0","timestamp":1789576413951,"price":4.35,"volume":2000,"amount":870000,"type":"*"}]},"impliedVol":0.3321,"impliedVolPercentile":0.784},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XBI\",,,,,undefined,":{"symbol":"XBI","floatShares":68750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.077362913566643,"shares":68750000,"dividePrice":0.5699,"high":156.04,"amplitude":0.022983,"preClose":154.03,"low":152.5,"week52Low":93.49,"pbRate":"--","week52High":169.89,"institutionHeld":0.8511,"latestPrice":154.18,"committee":-0.997503,"eps":18.23,"divideRate":0.003696,"volume":8853285,"delay":0,"ttmEps":18.23,"open":154.37,"prevYearClose":121.93,"prevWeekClose":156.2,"prevMonthClose":162.5,"prevQuarterClose":158.25,"fiveDayClose":159.38,"twentyDayClose":160.11,"sixtyDayClose":145.86},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XBI\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"XBI","amount":0.138094,"announcedDate":"2026-06-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-24","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-24"},{"date":"2025-12-22","symbol":"XBI","amount":0.406564,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-24"},{"date":"2025-09-22","symbol":"XBI","amount":0.02665,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-24","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-24"},{"date":"2025-06-23","symbol":"XBI","amount":0.007295,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-25","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-25"},{"date":"2025-03-24","symbol":"XBI","amount":0.00525,"announcedDate":"2025-03-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-24","defaultRemindTime":1742823000000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-26","payableDate":"2025-03-24","currency":"USD","dateTimestamp":1742788800000,"payDate":"2025-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XBI\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-27","value":0.01831,"currency":"USD"},{"executeDate":"2017-03-17","recordDate":"2017-03-21","paymentDate":"2017-03-27","value":0.019702,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-26","value":0.110135,"currency":"USD"},{"executeDate":"2017-09-15","recordDate":"2017-09-18","paymentDate":"2017-09-25","value":0.03704,"currency":"USD"},{"executeDate":"2018-03-16","recordDate":"2018-03-19","paymentDate":"2018-03-21","value":0.059081,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XBI\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XBI\",pageSize:20,pageCount:10,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1141376784","title":"醫療保健板塊快訊：市場動態綜述","url":"https://stock-news.laohu8.com/highlight/detail?id=1141376784","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141376784?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 00:24","pubTimestamp":1786638273,"startTime":"0","endTime":"0","summary":"医疗保健行业最新市场动态速览。该报道内容精选自专题市场快讯。该协会援引内部调查数据称，从去年1月到今年6月，Interpharma的成员企业，在总共22款新药中，有7款拒绝向瑞士医保机构提交报销申请。Interpharma表示，为了不危及美国市场的定价，药企往往会搁置其研发的新药，平均每三款就有一款暂停提交申请。KPJ Healthcare第二季度核心净利润预计将环比走强。该股目前股价持平，报3.07林吉特。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","XBI","BK4581","XLV","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161156613","title":"醫療保健板塊綜述：市場快訊","url":"https://stock-news.laohu8.com/highlight/detail?id=1161156613","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161156613?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 16:24","pubTimestamp":1786609477,"startTime":"0","endTime":"0","summary":"以下为最新医疗保健板块市场快讯，内容涵盖亚太及北美市场动态。RHB维持对KPJ的“买入”评级，目标股价定为3.77林吉特。Apotex公司在公开市场首秀中，其美国业务部门成为明显的软肋。该丹麦制药商的CEO似乎对减肥药丸市场的前景非常乐观，但贝伦贝格认为，诺和诺德可能需要通过交易来增加更多的口服药物，以维持其领先地位。贝伦贝格将诺和诺德股票的评级从“买入”下调至“持有”，并将目标价从325丹麦克朗下调至305丹麦克朗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","BK4588","XBI","XLV","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659182162","title":"上海：完善上海市重點產業地圖，聚焦集成電路、生物醫藥、人工智能三大先導產業","url":"https://stock-news.laohu8.com/highlight/detail?id=2659182162","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659182162?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 10:14","pubTimestamp":1786587282,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09834","ARTY","NOCT","OGIG","QQA","AGIX","AIBU","GK","NAPR","09086","LCLG","NJAN","DQJN","AQGX","QSWN","QQQ","AIQU","FWD","NBDS","WPAI","TQQQ","03086","NJUL","QQQM","TARK","KOMP","CHAT","TECY","GPIQ","XBI","AIFD","QTOC","MFIG","07266","VUSE","03034","03455","MVPS","NEWZ","QQQX","QMAR","SQQQ","CWC","PSQ","TQQY","QDEC","QLD","CPNQ","QID","PBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658974771","title":"民祥生物醫藥被出具警示函，涉未披露年報等","url":"https://stock-news.laohu8.com/highlight/detail?id=2658974771","media":"蓝鲸财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658974771?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 19:44","pubTimestamp":1786535098,"startTime":"0","endTime":"0","summary":"蓝鲸新闻8月12日讯，近日，天津证监局发布行政监管措施决定书，剑指天津民祥生物医药股份有限公司及相关责任人。决定书显示，民祥医药存在以下情形：未按规定披露2025年年度报告，补充披露相关人事及股东会决议公告不及时，为子公司提供担保未履行审议程序及信息披露义务。以上行为违反了《非上市公众公司监督管理办法》和《非上市公众公司信息披露管理办法》的相关规定。公司董事长刘万里、副总经理兼董秘张毅对上述违规事项负有责任。针对上述违法行为，天津证监局对民祥医药、刘万里、张毅采取出具警示函的监督管理措施，记入证券期货市场诚信档案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1786526206112430419","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["399441","BK4581","XBI","161726","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658921870","title":"花旗(C.US)調整北美醫療健康投行團隊 強化醫療賽道核心競爭力","url":"https://stock-news.laohu8.com/highlight/detail?id=2658921870","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658921870?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 14:25","pubTimestamp":1786515916,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗集团近日为医疗健康投行业务线新任命多名主管，计划借此提升行业地位，在火热的医疗赛道强化核心竞争力。全球医疗健康投行主管Sumit Khedekar发布内部备忘录称，本次调整敲定了北美地区生物科技、医疗器械、生物制药等多个医疗细分领域新任负责人人选。花旗银行业务主管Vis Raghavan今年5月在投资者大会上明确指出，医疗健康与科技、工业板块并列为三大高增长赛道，是花旗投行团队的重点攻坚方向。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478890.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2462157665.USD","LU1201861249.SGD","LU0128525689.USD","LU1366192091.USD","LU0052756011.USD","LU2125154935.USD","LU2456880835.USD","LU0170899867.USD","XLV","BK4588","BK4566","BK4585","LU1267930227.SGD","TFNS","LU2417539215.USD","LU0203345920.USD","LU1244550577.SGD","LU0648001328.SGD","LU0980610538.SGD","LU1791807156.HKD","VHT","159891","LU0162691827.USD","LU2360032135.SGD","LU0314106906.USD","LU1162221912.USD","LU0130517989.USD","LU1244550221.USD","FTXO","IYF","LABU","LU0098860793.USD","LU0106831901.USD","LU1074936037.SGD","LU0310800965.SGD","BK4207","BK4559","BK4581","LU0130102774.USD","BK4504","BK4550","IXJ","LU1506573853.SGD","LU0072461881.USD","LU2236285917.USD","XBI","LU1668664300.SGD","LU0203347892.USD","LU0320765646.SGD","159760"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658092329","title":"辰欣藥業等成立生物科技公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2658092329","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658092329?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 12:37","pubTimestamp":1786509464,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","BK4588","LNGR","AGNG","IEIH","MEDX","IBBJ","SYNB","GDOC","XBI","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658941844","title":"生物醫藥賽道迎來機構扎堆調研 商業化與全球化進展成關注重點","url":"https://stock-news.laohu8.com/highlight/detail?id=2658941844","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658941844?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 07:02","pubTimestamp":1786489344,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XBI","BK4581","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658963570","title":"人工智能公司Anthropic已告知部分投資者，該公司計劃進一步拓展醫療保健與生物學領域業務。","url":"https://stock-news.laohu8.com/highlight/detail?id=2658963570","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658963570?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 09:02","pubTimestamp":1786410136,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LCLG","FWD","CGVV","NJAN","NOCT","QSWN","WPAI","QTOC","QQA","ARTY","PBOT","PSQ","NOBL","DQJN","AIFD","GK","AQGX","CHAT","QLD","CWC","VHT","QQQX","XBI","GPIQ","MFIG","NAPR","NBDS","KOMP","TARK","AIQU","XLV","OGIG","MVPS","QID","QQQ","AGIX","QMAR","TECY","QQQM","LABU","CPNQ","TQQQ","NJUL","NEWZ","07568","VUSE","AIBU","QDEC","TQQY","SQQQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137780649","title":"醫療板塊綜述：市場快評","url":"https://stock-news.laohu8.com/highlight/detail?id=1137780649","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137780649?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 04:52","pubTimestamp":1786395164,"startTime":"0","endTime":"0","summary":"医疗板块最新市场快讯如约而至。本次快评内容聚焦于多家药企与医疗器械公司的动态，梳理了从晚期临床试验到财年业绩的各类关键信号。诺华股价当日微涨 0.3%。病理学服务提供商 Integral Diagnostics 的 2026 财年初步业绩，则令人失望。该公司预计年度营收在 7.88 亿至 7.90 亿澳元之间，低于市场普遍预期的 7.99 亿澳元。其运营息税折旧摊销前利润预计为 1.64 亿至 1.65 亿澳元，同样未能达到市场 1.69 亿澳元的预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4585","BK4581","XLV","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181671001","title":"醫療保健板塊動態：市場速評","url":"https://stock-news.laohu8.com/highlight/detail?id=1181671001","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181671001?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 00:22","pubTimestamp":1786378967,"startTime":"0","endTime":"0","summary":"最新的一轮医疗保健板块市场速评已出炉，信息发布时间分别为美国东部时间凌晨4:20、中午12:20及下午4:50。0339 EDT - 诺华旗下降胆固醇新药pelacarsen，其一项晚期试验的成功概率，如今正悬念重重。摩根大通认为，该药物达到这一门槛的可能性仅有40%。该公司预计全年营收在7.88亿至7.90亿澳元之间，远低于市场普遍预期的7.99亿澳元。在本周初，该机构对该股维持“跑赢大盘”评级，目标价为每股2.85澳元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","XLV","BK4585","BK4581","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193258586","title":"新聞稿：Ernexa Therapeutics 引入資深生物技術高管 David Polinsky 加入董事會，為臨床階段衝刺蓄力","url":"https://stock-news.laohu8.com/highlight/detail?id=1193258586","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193258586?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 21:09","pubTimestamp":1786367399,"startTime":"0","endTime":"0","summary":"此次任命正值公司关键转折点，进一步强化了其领导团队——Ernexa 正全力推进其核心项目 ERNA-101，计划于2026年第三季度提交新药临床试验申请，并在第四季度启动首项一期临床研究。马萨诸塞州剑桥市，2026年8月10日——Ernexa Therapeutics，一家致力于开发创新细胞疗法以治疗晚期癌症和自身免疫性疾病的行业先锋，今日宣布任命 David Polinsky 为其董事会成员。“我们正步入 Ernexa 历史上最为重要的时期之一，”Ernexa Therapeutics 总裁兼首席执行官 Sanjeev Luther 表示。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139","BK4588","LENZ","BK4585","SYNB","BK4007","RFL","BK4233","IBB","IND","XBI","BBP","BK4581","BK4205","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124588838","title":"醫療保健板塊市場動態速覽","url":"https://stock-news.laohu8.com/highlight/detail?id=1124588838","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124588838?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 16:29","pubTimestamp":1786350589,"startTime":"0","endTime":"0","summary":"0729 GMT - 摩根大通分析师发布报告指出，诺华制药旗下降胆固醇药物pelacarsen的晚期试验前景尚不明朗。据摩根大通测算，这一结果发生的概率仅为40%。诺华股价微涨0.3%。该公司预计年度营收为7.88亿至7.90亿澳元，低于市场普遍预期的7.99亿澳元。其运营息税折旧摊销前利润预计为1.64亿至1.65亿澳元，也未达到市场预期的1.69亿澳元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","XBI","BK4581","XLV","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658609667","title":"港股生物醫藥股盤初走高，藥明康德股價突破200港元關口創歷史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2658609667","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658609667?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 09:51","pubTimestamp":1786326707,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端港股生物医药股盘初走高，药明康德一度涨超5%，股价突破200港元关口创历史新高，现涨超4%；再鼎医药涨超5%，诺诚建华、药明生物涨超3%。开源证券发布研报表示，投资上，我们建议重点关注减重代谢领域中口服司美格鲁肽及Foundayo两个确定性的增量机会。同时，药明康德小分子D&M 业务大体量下加速增长，预示着国内小分子CDMO 板块有望在未来3-5年迎来增长新周期，相关公司的签单收入有望逐步加速，利润端有望超预期增长。","market":"hk","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2026-08-10/doc-inimuvrt8236475.shtml","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0348766576.USD","XBI","BK1583","LU1997245177.USD","BK0216","BK1576","EWH","BK4585","IE00B543WZ88.USD","LU0456842615.SGD","LU1997245094.SGD","LU2045819591.USD","VXUS","LU0052750758.USD","02359","LU1251922891.USD","LU0348767384.USD","LU2242644610.SGD","LU2125910500.SGD","09969","LU1303224171.USD","BK4581","IE00BPRC5H50.USD","LU0700851271.USD","LU0320764599.SGD","161726","IE00B5MMRT66.SGD","BK4588","09688","LU1934453819.USD","LU0611395673.USD","LU1046422090.SGD","LU0708995583.HKD","LU2328871848.SGD","LU1808992512.USD","LU1997244956.HKD","LU2488822045.USD","LU2495084118.USD","LU1770034418.SGD","KCAI","BK1141","LU1979443071.USD","LU1719994722.HKD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131279132","title":"醫療保健板塊動態：市場快訊匯總","url":"https://stock-news.laohu8.com/highlight/detail?id=1131279132","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131279132?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 16:22","pubTimestamp":1786177346,"startTime":"0","endTime":"0","summary":"这些内容独家发布于道琼斯新闻社，分别在美东时间4:20、12:20和16:50。赛诺菲股价上涨2%，再生元股价则基本持平。第二季度调整后营业利润超出预期16%，主要得益于20亿丹麦克朗的回扣调整。该药企Wegovy药片的销售额略低于市场共识，而其美国注射剂销量则低于预期9%。花旗补充称，全年业绩指引上调已在预期之内，而CagriSema在与礼来替尔泊肽的头对头试验中失败，进一步打击了市场信心。该股上涨4.7%，报307.38克朗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","XBI","BK4581","XLV","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657276226","title":"人民健康保險天津分公司被罰28萬，涉欺騙投保人","url":"https://stock-news.laohu8.com/highlight/detail?id=2657276226","media":"蓝鲸财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657276226?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 14:22","pubTimestamp":1786170134,"startTime":"0","endTime":"0","summary":"蓝鲸新闻8月8日讯，近日，国家金融监督管理总局天津监管局发布行政处罚决定书，剑指中国人民健康保险股份有限公司天津分公司及相关责任人。罚单显示，中国人民健康保险股份有限公司天津分公司的主要违法违规行为是：欺骗投保人。针对上述违法行为，国家金融监督管理总局天津监管局对中国人民健康保险股份有限公司天津分公司罚款28万元；对闻伟禁止终身进入保险业。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1786167414374667463","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4581","BK4585","LABU","BK4588","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657627583","title":"梁振英：在醫療健康領域香港也可成為「超級聯繫人」","url":"https://stock-news.laohu8.com/highlight/detail?id=2657627583","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657627583?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 13:17","pubTimestamp":1786166220,"startTime":"0","endTime":"0","summary":"梁振英表示，香港的价值定位是作为内地与其他国家之间的“超级联系人”。梁振英指出，如果把这套逻辑推演到医疗健康领域，未来香港完全有机会充当连接角色，搭建双向桥梁，对接全球供给与中国需求，同时对接中国供给与全球需求，这并非空想，而是长期目标，目前才刚刚起步。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-08-08/doc-inimqptv6574030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XBI","BK4581","IXJ","LABU","VHT","159760","BK4588","BK4585","XLV","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183021512","title":"醫療保健板塊市場快訊","url":"https://stock-news.laohu8.com/highlight/detail?id=1183021512","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183021512?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 04:55","pubTimestamp":1786136134,"startTime":"0","endTime":"0","summary":"她认为该交易按当前方案完成的可能性为75%，但鉴于Jamieson的“优质资产”属性、在加拿大的领先市场份额，以及预计至2028年收入复合年增长率达11%，存在25%的可能性出现更高报价。消息公布后，TD将目标股价从48加元上调至49加元，以反映概率加权结果，但将评级从“买入”下调至“持有”。该股盘中上涨9.6%，报45.47加元。** 欧洲斯托克600指数上涨0.2%，软件和医疗保健板块领涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","XLV","BK4581","LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145080185","title":"醫療健康板塊綜述：市場動態快報","url":"https://stock-news.laohu8.com/highlight/detail?id=1145080185","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145080185?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 00:23","pubTimestamp":1786119809,"startTime":"0","endTime":"0","summary":"她在报告中坦言，“对报价未达预期感到惊讶”。该分析师认为，按当前方案完成交易的概率为75%，但同时存在25%的可能性，因Jamieson具备“优质资产”属性、在加拿大市场占据领先份额，且预计至2028年收入复合年增长率达11%，报价有望被上调。消息公布后，TD将目标股价从48加元上调至49加元，以反映概率加权结果，同时将评级从“买入”下调至“持有”。该股现涨9.6%，报45.47加元。泛欧斯托克600指数上涨0.2%，软件与医疗健康板块领涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4581","BK4588","BK4585","LABU","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657649773","title":"人保健康天津分公司因欺騙投保人被罰28萬元 一人被終身禁業","url":"https://stock-news.laohu8.com/highlight/detail?id=2657649773","media":"金融一线","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657649773?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 21:36","pubTimestamp":1786109760,"startTime":"0","endTime":"0","summary":"8月7日金融一线消息，国家金融监督管理总局天津监管局行政处罚信息公开表显示，中国人民健康保险股份有限公司天津分公司因欺骗投保人，被罚款28万元。闻伟被禁止终身进入保险业。序号当事人名称主要违法违规行为行政处罚内容作出决定机关1中国人民健康保险股份有限公司天津分公司欺骗投保人。对中国人民健康保险股份有限公司天津分公司罚款28万元；对闻伟禁止终身进入保险业国家金融监督管理总局天津监管局","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jryx/fd/2026-08-07/doc-inimnzse9955329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4581","XBI","BK4588","XLV","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657643444","title":"胡偉獲批擔任人保健康董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2657643444","media":"金融一线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657643444?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 20:09","pubTimestamp":1786104540,"startTime":"0","endTime":"0","summary":"8月7日金融一线消息，国家金融监督管理总局发布《关于胡伟中国人民健康保险股份有限公司董事任职资格的批复》，核准胡伟中国人民健康保险股份有限公司董事的任职资格。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jryx/hm/2026-08-07/doc-inimnzsm4704005.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LABU","BK4588","XBI","BK4581","BK4585","XLV"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}